Drug Profile
Research programme: liver disorder therapeutics - Revive Therapeutics/South Carolina Research Foundation
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator University of South Carolina
- Developer Revive Therapeutics; Sanyal Biotechnology
- Class Cannabinoids; Hepatoprotectants
- Mechanism of Action Cannabinoid receptor CB1 modulators; Cannabinoid receptor CB2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune hepatitis; Liver disorders
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Autoimmune-hepatitis in USA
- 28 Oct 2021 No recent reports of development identified for research development in Liver-disorders in USA
- 18 Feb 2020 Revive Therapeutics announces intention to submit NDA to the US FDA for Autoimmune hepatitis